Novel Triple Agonist Nabs Biggest Weight Loss Yet in Obesity Trial
SAN DIEGO -- An investigational triple-hormone receptor agonist yielded major weight loss in people with obesity,…
Browsing Tag
Agonist
Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in…
- Marked increases in overall survival observed across soft tissue sarcoma patients - - Demonstrated improvement of median progression free survival in patients with dedifferentiated…
Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for…
<!-- Name:DistributionId Value:8846943 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be…
<!-- Name:DistributionId Value:8804517 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Buprenorphine for Chronic Pain, Not Full Agonist Opioids, New VA Guidance Says
Buprenorphine, rather than a full agonist opioid, should be used for patients taking daily…
Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in…
First-in-human data shared at The Liver Meeting® 2022 supported a favorable safety and tolerability profile for INT-787 in healthy adults Company announces severe alcohol-associated…
Kineta to Present Anti-CD27 Agonist Preclinical Program at AACR Conference on Tumor…
SEATTLE, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in…
Lenabasum, a cannabinoid receptor agonist, is an effective and safe treatment for…
A recent study in the Journal of Investigative Dermatology describes the success of using lenabasum, a cannabinoid receptor type 2 (CB2) agonist that triggers the resolution of inflammation,…
Sosei Heptares’ Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical…
Neurocrine to conduct placebo-controlled Phase 2 study to investigate NBI-1117568 (formerly HTL-0016878) as a potential new treatment for schizophrenia Clinical development milestone…
IL-15 Agonist Impresses in Non-Muscle Invasive Bladder Cancer
CHICAGO -- Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) had a high response rate and 2-year…